William Chou
Vermogen: 31 837 $ op 30-06-2026
Vermogen: 31 837 $ op 30-06-2026
Dr. William Chou is a President, Chief Executive Officer & Director at Passage Bio, Inc. He is on the Board of Directors at Passage Bio, Inc. Dr. Chou was previously employed as a Chief Executive Officer by Aruvant Sciences, Inc. and a Vice President by Novartis Pharma AG.
He received his undergraduate degree from Princeton University, an MBA from Yale School of Management and a doctorate degree from the University of Pittsburgh School of Medicine.
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 16-03-2026 | 6.524 ( 0,2% ) | 31 837 $ | 30-06-2026 |
| Bedrijven | Functie | Begin |
|---|---|---|
| PASSAGE BIO, INC. | Algemeen Directeur | 10-10-2022 |
| Bedrijven | Functie | Einde |
|---|---|---|
Aruvant Sciences, Inc.
Aruvant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes gene therapies for hematological diseases utilizing reduced-intensity conditioning | Algemeen Directeur | 01-10-2022 |
Novartis Pharma AG
Novartis Pharma AG Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company | Corporate Officer/Principal | 01-10-2019 |
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
| Bedrijven in privébezit | 6 |
|---|---|
Princeton University
Princeton University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Novartis Pharma AG
Novartis Pharma AG Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company | Health Technology |
Yale School of Management
Yale School of Management Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Pittsburgh School of Medicine
University of Pittsburgh School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Passage Bio, Inc.
Passage Bio, Inc. BiotechnologyHealth Technology Develops therapies for the treatment of monogenic central nervous system disorders | Health Technology |
Aruvant Sciences, Inc.
Aruvant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes gene therapies for hematological diseases utilizing reduced-intensity conditioning | Health Technology |
Kies jouw editie
Alle financiële informatie op nationaal niveau